FinancialBuzz.com’s latest


The Buzz


Show: Featuring Our Corporate News Recap on “Chembio Diagnostics, Inc. Launches Commercial Distribution of Third-Party COVID-19 Antigen Test”

Chembio Diagnostics, Inc. (NYSE: CEMI)


climbed over 13% in premarket trading after the company announced its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point-of-care COVID-19 antigen test.

The test can be used for both patients who are suspected of COVID-19 by their healthcare provider within 5 days of symptom onset as well as for asymptomatic serial testing and provides results in 20 minutes from a nasal swab with no instrumentation required.

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease.

For more information, please visit:


Chembio Diagnostics, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post

“The Buzz” Show: Chembio Diagnostics, Inc. (NYSE: CEMI) Distribution of Third-Party COVID-19 Test

first appeared on

Financial Buzz

.

For further details see:

“The Buzz” Show: Chembio Diagnostics, Inc. (NYSE: CEMI) Distribution of Third-Party COVID-19 Test